Original-Research: NanoRepro AG (von NuWays AG): BUY

What happened

NuWays AG rated NanoRepro AG a BUY. NanoRepro reported stronger-than-expected Paedi Protect sales, ongoing cost savings at the holding level, and a first drugstore listing for newkee. Consolidated FY25 and H1 26 reports are delayed to the end of 2026.

Confirmed

Global impact / market context

The drugstore listing gives newkee a physical retail channel, which can lift product revenue and brand visibility beyond online sales. Cost savings at the holding level support cash available, while delayed consolidated reports keep investors without a full group financial picture until year-end 2026.

Analyst inference

A BUY rating signals the analyst expects share price gains over 12 months. The commercial update, including stronger Paedi Protect sales and the newkee listing, supports the platform strategy, but reporting delays add uncertainty around group-wide revenue and costs.

Analyst inference

What to watch

1. Consolidated FY25 and H1 26 reports are now due by the end of 2026, after additional consolidation-related work and accounting harmonization under the new CFO who started in October 2026. Confirmed
2. Watch whether the first drugstore listing for newkee expands to more retail partners, which would raise product revenue and test whether the platform strategy can scale beyond its initial launch. Proposed
3. Track whether stronger Paedi Protect sales and holding-level cost savings carry into future periods, since these drive profit per sale and cash available while full group figures remain unavailable. Analyst inference

Evidence

• eqs-news.com